Myriad Genetics, Inc.

    Jurisdiction
    United States
    LEI
    52990044IHUOUMETT163
    ISIN
    US62855J1043 (MYGN)
    Sectors
    1. Healthcare
    2. Medical - Diagnostics & Research

    Scores

    InsiderPie Expert Score
    trending_flat 50 / 100
    Even with peer group:
    51 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    3 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    4 / 7

    Profile

    Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €717.58M
    Gross margin
    70.4%
    EBIT
    -€359.44M
    EBIT margin
    -50.1%
    Net income
    -€340.48M
    Net margin
    -47.4%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €748.45M +4.3% €8.32M -102.4%
    €791.40M +5.7% €17.78M +113.7%
    €822.66M +3.9% €22.53M +26.7%

    Dividends

    Last dividend amount
    $1.75
    Ex date

    Earnings Calls

    Latest earnings call: May 7, 2024

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 250K $2.22M -435K Sell

    Add to watchlist

    Notifications